GSK's Consumer Segment Grows 7% With Heavy Investment In R&D And A&P
This article was originally published in The Tan Sheet
Executive Summary
Increased investment in brand innovation and high-quality, high-volume advertising are the "underpinning" of GlaxoSmithKline's consumer segment's "spectacular year," according to CEO Andrew Witty
You may also be interested in...
GSK Expands In Korea With Purchase Of Equity Stake In Dong-A Pharma
GlaxoSmithKline is paying 142.9 billion South Korean won ($128.7 million) to acquire a 9.9 percent stake in Dong-A Pharmaceutical, South Korea's leading Rx and OTC company. The strategic alliance should help GSK gain share in the rapidly growing Korean pharmaceutical market
GSK Names Top L'Oreal Executive To Lead Consumer Business
GlaxoSmithKline underscores the importance of emerging markets to its growth strategy by appointing to lead its consumer division a top L'Oreal executive with a track record of building brands in China and established markets
Glaxo Iso-Active Toothpastes Employ Double Foam, Claim Triple Efficacy
GlaxoSmithKline is replacing the conventional toothpaste tube with a canister like those used for shaving products to deliver its new Aquafresh and Sensodyne products with "twice the foam volume as ordinary toothpaste.